Novan

Novan Phase 3 Pivotal Trials Fully Enrolled

Novan has announced that the last patient has been randomized in its two identically designed Phase 3 pivotal clinical trials to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris. More than 2,600 subjects have been enrolled ahead of schedule, and Novan expects to report top-line results in the first quarter of 2017.

The company’s Phase 3 program includes three studies:

Phase 3 Trials Initiated for Nitric Oxide Acne Treatment

Phase 3 Trials Initiated for Nitric Oxide Acne Treatment

Novan announced that the first patient has been dosed in its Phase 3 trial to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris. The company anticipates reporting the results from the two identically designed Phase 3 pivotal trials in the first half of 2017.

Novan’s Phase 3 program includes three studies:

Novan Appoints New CFO and CCO

Novan Therapeutics, developer of investigational acne product SB204, has announced the addition of two executives from the dermatology industry to the its leadership team. Richard Peterson, formerly of Medicis International, has joined the company as Chief Financial Officer and Brian Johnson, formerly of Galderma and Medicis International, as Chief Commercial Officer. Peterson will be responsible for the company's financial operations, investor relations and other corporate functions.

Novan Announces Positive Phase 2 Results for Novel Acne Treatment

Novan Therapeutics, a specialty pharmaceutical company focused on medical nitric oxide therapies has announced positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. The Phase 2 study was a double blind, vehicle-controlled, dose-ranging study conducted in 150 subjects with acne. Subject were randomized evenly to 1% SB204, 4% SB204, or vehicle gel and treated for 12 weeks. SB204 demonstrated good cutaneous tolerability with no reported serious adverse events.

Novan Awarded $7.8 Million Contract To Develop Thermal Burn Treatment

Burn patients may soon have a new treatment option available, as the U.S. Department of Health and Human Services has entered into a contract with Novan Therapeutics (www.novantherapeutics.com) to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, will provide funding of $7.8 million over two years.